Allogeneic CAR-T cells: more than ease of access?

Graham, Charlotte, Jozwik, Agnieszka, Pepper, Andrea and Benjamin, Reuben (2018) Allogeneic CAR-T cells: more than ease of access? Cells, 7 (10). p. 155. ISSN 2073-4409

[img] PDF - Published Version
Available under License Creative Commons Attribution.

Download (616kB)


Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in
achieving a complete remission in a range of B-cell malignancies, most notably B-acute lymphoblastic
leukaemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). However, there are limitations,
including inability to manufacture CAR-T cells from the patient’s own T cells, disease progression
and death prior to return of engineered cells. T cell dysfunction is known to occur in cancer patients,
and several groups have recently described differences in CAR-T cells generated from chronic
lymphocytic leukaemia (CLL) patients compared with those from a healthy donor. This is thought
to contribute to the low response rate in this disease group. Healthy donor, gene-edited CAR-T
cells which do not require human leucocyte antigen (HLA) matching have the potential to provide
an ‘off the shelf’ product, overcoming the manufacturing difficulties of producing CAR-T cells for
each individual patient. They may also provide a more functional, potent product for malignancies
such as CLL, where T cell dysfunction is common and frequently cannot be fully reversed during
the manufacturing process. Here we review the potential benefits and obstacles for healthy donor,
allogeneic CAR-T cells.

Item Type: Article
Keywords: CAR-T cells; cancer immunotherapy; gene editing
Schools and Departments: Brighton and Sussex Medical School > Clinical and Experimental Medicine
Subjects: R Medicine
Depositing User: Gemma Hamilton
Date Deposited: 04 Oct 2018 10:50
Last Modified: 04 Oct 2018 10:50

View download statistics for this item

📧 Request an update